Neurogene Inc. short interest in 2023
In 2023, Neurogene Inc.'s disclosed short interest ran from 0.55% of shares outstanding on 13 Jan 2023 to 0.37% on 15 Dec 2023, a change of -0.18 percentage points. The year's high was 1.37% on 15 Mar 2023 and its low 0.27% on 31 Aug 2023, averaging 0.59% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.24 days on 31 Jan 2023. Full history: Neurogene Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 0.55% (13 Jan 2023)
- End of year
- 0.37% (15 Dec 2023)
- Change
- -0.18 pp
- High
- 1.37% (15 Mar 2023)
- Low
- 0.27% (31 Aug 2023)
- Average
- 0.59%
- Highest days to cover
- 4.24 (31 Jan 2023)
- SEC filings marked
- 4
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 0.55% | 1.06 | |
| 31 Jan 2023 | 0.61% | 4.24 | |
| 15 Feb 2023 | 0.76% | 2.08 | |
| 28 Feb 2023 | 0.56% | 1.76 | |
| 15 Mar 2023 | 1.37% | 1.00 | |
| 31 Mar 2023 | 1.35% | 1.99 | 10-K filed |
| 14 Apr 2023 | 0.84% | 1.41 | |
| 28 Apr 2023 | 0.71% | 1.19 | |
| 15 May 2023 | 0.58% | 1.74 | 10-Q filed |
| 31 May 2023 | 0.54% | 2.57 | |
| 15 Jun 2023 | 0.49% | 4.02 | |
| 30 Jun 2023 | 0.53% | 2.24 | |
| 14 Jul 2023 | 0.52% | 3.02 | |
| 31 Jul 2023 | 0.42% | 1.00 | |
| 15 Aug 2023 | 0.29% | 1.00 | 10-Q filed |
| 31 Aug 2023 | 0.27% | 1.00 | |
| 15 Sep 2023 | 0.49% | 1.46 | |
| 15 Nov 2023 | 0.29% | 2.80 | 10-Q filed |
| 30 Nov 2023 | 0.28% | 1.42 | |
| 15 Dec 2023 | 0.37% | 1.12 |
See also: Neurogene Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.